Caelum Biosciences Overview
- Year Founded
-
2015

- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$500M
Caelum Biosciences General Information
Description
Operator of a clinical-stage biotechnology comapny intended to develop treatments for rare and life-threatening conditions. The company is engaged in development of antibodies that work to break up pre-existing amyloid in tissues and to help the body's immune system remove the deleterious material, enabling patients with a greater chance to be a safe, receive well-tolerated therapy that promotes amyloid resolution and improve organ responses.
Contact Information
Website
www.caelumbio.comCorporate Office
- Rutgers Ecocomplex
- 1200 Florence Road
- Bordentown, NJ 08505
- United States
Corporate Office
- Rutgers Ecocomplex
- 1200 Florence Road
- Bordentown, NJ 08505
- United States
Caelum Biosciences Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Merger/Acquisition | 06-Oct-2021 | $500M | Completed | Clinical Trials - Phase 3 | ||
1. Early Stage VC | 30-Jan-2019 | Completed | Clinical Trials - Phase 3 |
Caelum Biosciences Comparisons
Industry
Financing
Details
Caelum Biosciences Competitors (56)
One of Caelum Biosciences’s 56 competitors is Adverum Biotechnologies, a Formerly VC-backed company based in Redwood City, CA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA | ||||
Meditope Biosciences | Venture Capital-Backed | Pasadena, CA | ||||
Apeptico | Venture Capital-Backed | Vienna, Austria | ||||
NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
Glycomine | Venture Capital-Backed | San Carlos, CA |
Caelum Biosciences Patents
Caelum Biosciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3231073-A1 | Method of treating multiple myeloma | Pending | 14-Sep-2021 | ||
EP-4401839-A2 | Method of treating multiple myeloma | Pending | 14-Sep-2021 | ||
AU-2022346750-A1 | Method of treating multiple myeloma | Pending | 14-Sep-2021 | ||
US-20240392028-A1 | Method of treating multiple myeloma | Pending | 14-Sep-2021 | ||
AU-2021339851-A8 | Method of treating amyloidosis | Pending | 14-Sep-2020 | C07K16/18 |
Caelum Biosciences Former Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Columbia Technology Ventures | University | Minority |
Caelum Biosciences FAQs
-
When was Caelum Biosciences founded?
Caelum Biosciences was founded in 2015.
-
Where is Caelum Biosciences headquartered?
Caelum Biosciences is headquartered in Bordentown, NJ.
-
What industry is Caelum Biosciences in?
Caelum Biosciences’s primary industry is Biotechnology.
-
Is Caelum Biosciences a private or public company?
Caelum Biosciences is a Private company.
-
What is the current valuation of Caelum Biosciences?
The current valuation of Caelum Biosciences is
. -
What is Caelum Biosciences’s current revenue?
The current revenue for Caelum Biosciences is
. -
How much funding has Caelum Biosciences raised over time?
Caelum Biosciences has raised $69.9M.
-
Who are Caelum Biosciences’s investors?
Columbia Technology Ventures has invested in Caelum Biosciences.
-
Who are Caelum Biosciences’s competitors?
Adverum Biotechnologies, Meditope Biosciences, Apeptico, NexImmune, and Glycomine are some of the 56 competitors of Caelum Biosciences.
-
When was Caelum Biosciences acquired?
Caelum Biosciences was acquired on 06-Oct-2021.
-
Who acquired Caelum Biosciences?
Caelum Biosciences was acquired by Alexion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »